Biomarkers for improving the (cost-)effectiveness and safety of pemetrexed

Recruiting

• Conditions: lung cancer; non small cell lung carcinoma; 10038666

• Registration Number: NL-OMON39476
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

patients with non-small cell, non-squamous lungcarcinoma or malignant pleural mesothelioma who have an indication for treatment with pemetrexed containing chemotherapy, both in first line treatment as in following treatment lines and as maintenance therapy.

Exclusion Criteria

non able to read dutch
clinical condition not fit to receive pemetrexed chemotherapy

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>This is an observational study. The primairy outcome is the question whether<br /><br>there is a relation between pharmacogenetics and pharmacokinetics and repons to<br /><br>treatment with pemetrexed</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>relation between pharmacogenetics and pharmacokinetics and quality of life</p><br>